Maximizing value through deep understanding of scientific and business goals
Tara L. Rachinsky, PhD counsels clients in the life sciences, including the biotechnology, pharmaceutical, chemical, and medical device fields. Drawing on her extensive experience, she relies on a thorough understanding of the client's research and business goals to develop strategies to derive maximum value from technology. This includes worldwide intellectual property portfolio creation, strategy, and management, including patent preparation and prosecution. She also provides freedom-to-operate, patentability, validity, and non-infringement opinions, as well as due diligence analyses in support of business transactions.
Tara works with companies of all sizes, from start-ups to publicly-traded corporations, as well as research foundations and universities. She represents clients with inventions in a variety of technologies, including recombinant nucleic acids and proteins, diagnostics and biomarkers, gene therapy, agricultural biology, immunology, small molecule chemistry, bioinformatics, microbiology, medical imaging, drug delivery compositions and devices, biomaterials, nanotechnology, human and veterinary nutrition, nutraceuticals, and consumer products.
Tara’s scientific experience includes neuroscience, pharmacology, and molecular biology. Her PhD dissertation focused on the molecular cloning and characterization of a gene encoding an enzyme essential for nervous system function. She conducted post-doctoral research on molecular development of the retina at the University of Chicago, where she was awarded a postdoctoral fellowship from the National Eye Institute. Additionally, she performed post-doctoral research at the University of Pennsylvania, where she implemented molecular and biochemical techniques in a neurophysiology laboratory to study gene expression involved in epilepsy.
Prior to joining McNeill Baur PLLC, Tara gained more than 18 years of experience as an intellectual property attorney, bringing to the table her experience as an in-house patent counsel, as well as a private practice attorney in both IP boutiques and large general practice firms.
“The future of prenatal molecular diagnostics: Impact of the changing patent landscape,” Pharmaceutical Patent Analyst, Vol. 3, No. 1, 1-3, January (2014).
“Basal expression and induction of glutamate decarboxylase and GABA in excitatory granule cells of the rat and monkey hippocampal dentate gyrus,” Journal of Comparative Neurology, 373: 593-618 (1996) (coauthor).
“Presence of mRNA for glutamic acid decarboxylase in both excitatory and inhibitory neurons,” Proceedings of the National Academy of Sciences, 93: 9844-9849 (1996) (coauthor).
“Structure and regulation of expression of the acetylcholinesterase gene,” Chemico-Biological Interactions, 87: 199-207 (1993) (coauthor).
“Promoter elements and transcriptional control of the mouse acetylcholinesterase gene,” Journal of Biological Chemistry, 268: 3563-3572 (1993) (coauthor).
“Assignment of the gene for acetylcholinesterase to distal mouse chromosome 5,” Genomics 14: 511-514 (1992) (coauthor).
“Gene structure of mammalian acetylcholinesterase: Alternative exons dictate tissue specific expression,” Journal of Biological Chemistry, 266: 23083-23090 (1991) (coauthor).
“Molecular cloning of mouse acetylcholinesterase: Tissue distribution of alternatively spliced mRNA species,” Neuron 5: 317-327 (1990) (coauthor).
“Single gene encodes glycophospholipid-anchored and asymmetric acetylcholinesterase forms: Alternative coding exons contain inverted repeat sequences,” Neuron 4: 289-301 (1990) (coauthor).
Select Speaking Engagements
"How the Changing Patent Landscape Will Impact the Future of Prenatal Molecular Diagnostics" Advances in Prenatal Molecular Diagnostics, Boston, MA, 2013.
"A Legal Primer for Scientists, Entrepreneurs, and Biotech Companies" Pennsylvania Biotechnology Center, Doylestown, PA 2012.
"Innovation through Co-Creation: Engaging Customers and Other Stakeholders" Mack Center for Technological Innovation, The Wharton School, University of Pennsylvania, Philadelphia, PA, 2011.
"Inequitable Conduct: A New Plague?" 20th Annual Join Patent Practice Seminar, New York, NY, 2004.